Skip to content

Insmed INSM Total costs & expenses

Total costs & expenses at other companies

United Therapeutics logo
United TherapeuticsUTHR
Incyte logo
IncyteINCY
Amgen logo
AmgenAMGN
ALN
Alnylam PharmaceuticalsALNY
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$21.34B+155%
Enterprise value$21.34B+142%
P/S26×+4.1×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's total costs & expenses?
Insmed (INSM) reported total costs & expenses of $459.28M in Q1 2026.
How has Insmed's total costs & expenses changed year-over-year?
Insmed's total costs & expenses increased by 34.7% year-over-year, from $340.96M to $459.28M.
What is the long-term trend for Insmed's total costs & expenses?
Over 4 years (2021 to 2025), Insmed's total costs & expenses has grown at a 34.7% compound annual growth rate (CAGR), from $563.56M to $1.85B.